<p><span style="color: #262626;">在生命科学研究范式发生深刻变革的今天，以蛋白组学及其前沿分支“空间蛋白组学”为代表的技术体系，已成为驱动源头创新与重大发现的引擎。它们不仅能够全景式解析生理病理过程中复杂的蛋白质表达、互作与动态变化，更能将关键的分子事件精准定位至特定的组织微区以及单个细胞，在空间维度上还原生命的真实架构与功能网络，为理解发育、疾病、免疫等核心生命过程提供了前所未有的视角。</span></p> <p><span style="color: #262626;">作为这一科研范式变革的坚定推动者，华盈生物始终致力于以前沿、完整、可定制的蛋白组学解决方案，赋能科学研究突破边界。在过去的一年中，我们荣幸地见证了众多合作伙伴在CNS及其子刊等国际顶级期刊上发表了一系列具有里程碑意义的高分研究成果。这些工作不仅解决了领域内的重要科学问题，更生动展现了以整合性、单细胞分辨率空间蛋白组学为主导的新研究范式的巨大价值——它正在系统性地揭开生命复杂性的层层面纱，引领基础研究与临床转化迈向更深刻、更精准的新阶段。我们期待继续以坚实的技术平台和深度的服务，与全国科研同仁携手，共同绘制更加精细的生命图谱，驱动更多源头创新。我们甄选了若干合作伙伴的标志性创新研究成果，以资交流与研讨。</span></p> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">1</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：复旦大学附属中山医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #262626;"><strong><span style="color: #ff0000;">C</span></strong><strong><span style="color: #ff0000;">e</span></strong><strong><span style="color: #ff0000;">ll (IF:</span></strong><strong><span style="color: #ff0000;">42.5</span></strong><strong><span style="color: #ff0000;">)</span></strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：<strong>Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance</strong></span></p> <p><span style="color: #262626;">该研究揭示了癌细胞通过ATF4-SLIT2-CGRP轴激活伤害感受神经元，远程重塑肿瘤引流淋巴结（TDLN）的免疫状态，从而逃避免疫监视的新机制，为联合神经调节和免疫治疗提供了理论基础。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>PCF空间单细胞蛋白组</strong></span><span style="color: #0987e0;">检测服务，助力研究者发现了众多免疫细胞中，只有肿瘤相关巨噬细胞（TAM）和伤害感受神经元具有显著的共定位关系，为揭示“TAM激活伤害感受神经元”的机制假说提供了直接的空间原位证据。</span></p> <section><img src="https://img.medsci.cn/e4345f172863f7232a9a7e6fb9bd7bc9493e3853d9fe894bbee0df89de3494ae.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">2</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：上海长征医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>C</strong><strong>e</strong><strong>ll (IF:</strong><strong>42.5</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>An iPSC-derived CD19/BCMA CAR-NK therapy in a</strong><strong> </strong><strong>patient with systemic sclerosis</strong></span></p> <p><span style="color: #262626;">该研究设计并开发了iPSC来源的CD19/BCMA双靶点的CAR-NK细胞产品QN-139b，并成功应用在一例难治性硬皮病患者中，为重症自身免疫病提供了变革性治疗方案。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>LCM-MS</strong><strong>空间蛋白组</strong></span><span style="color: #0987e0;">检测服务。LCM-MS空间蛋白组发现了CAR-NK灌输后，在患者皮肤的基底层、汗腺层、上皮层和真皮胶原层中不同的生物学通路被激活，揭示了QN-139b通过双靶点清除致病B细胞，可以重塑免疫稳态和逆转组织纤维化。</span></p> <section><img src="https://img.medsci.cn/77d64b54c3467374adbea43a55d16e4a35904189e606888767683089eef53307.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="">3</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：复旦大学附属华山医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong><span class="">Cancer Cell</span> (IF:</strong><strong>44.5</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy</strong></span></p> <p><span style="color: #262626;">该项研究探讨了STING信号通路在肿瘤免疫治疗中的复杂作用，特别是其诱导的肿瘤单核细胞中PD-L1的高表达对抗STING激动剂疗法产生耐药性的影响。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>PEX100信号通路磷酸化<span class="">抗体芯片</span>检测分析服务</strong></span><span style="color: #0987e0;">，系统解析了TLR2激活对STING下游JAK-STAT和NF-κB通路磷酸化水平的调控，为机制阐释提供了关键证据。</span></p> <section><img src="https://img.medsci.cn/028ac4a857b5ddb97c50062985c518b046f723a892fa91b8bd14aeca614d5fa8.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="2">4</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：中国医学科学院肿瘤医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers</strong></span></p> <p><span style="color: #262626;">这项研究全面描绘了小细胞肺癌（SCLC）的单细胞和空间图谱，系统解析了SCLC的肿瘤微环境组成和癌细胞异质性，并首次报道了FAK剪接变体可作为SCLC的预后标志物和治疗靶点。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>PCF空间单细胞蛋白组</strong></span><span style="color: #0987e0;">检测服务，助力研究者揭示了肿瘤组织和癌旁组织显著差异的免疫微环境特征，并发现了对免疫治疗反应不同的患者中，肿瘤细胞上抗原呈递分子<span class="">MHC</span>表达的显著异质性，为理解SCLC免疫逃逸机制提供了新视角。</span></p> <section><img src="https://img.medsci.cn/101926cb29d8f51d21361980c8e7f1483907dd5687c9554f11a18d78c19ce7be.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="3">5</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：上海长海医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：<strong>A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade</strong></span></p> <p><span style="color: #262626;">这项研究开发和验证了一种新型长效 C5a 阻断环肽（Cp1）在防治脓毒症中作用效果。</span></p> <p><span style="color: #0987e0;">华盈生物提供的</span><span style="color: #ff0000;"><strong>Luminex</strong><strong>细胞因子</strong><strong>检测服务</strong></span><span style="color: #0987e0;">协助研究团队全面评估了 Cp1 对炎症级联反应的阻断效果。通过对小鼠血浆及腹腔灌洗液中多种细胞因子与趋化因子的广谱筛查，证实了 Cp1 能显著抑制 IL-6、TNF-α 等关键因子的表达，从而有效遏制“细胞因子风暴”。</span></p> <section><img src="https://img.medsci.cn/fe5dd7213d7fb50b3c2c281336296a5bd6ecd34a799693b7e2027ee40c03f04e.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="4">6</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：清华大学</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Signal Transduct Target Ther (IF: 52.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Clinical investigation on nebulized human umbilical cord</strong><strong> </strong><strong>MSC-derived extracellular vesicles for pulmonary</strong><strong>fi</strong><strong>brosis</strong><strong> </strong><strong>treatment</strong></span></p> <p><span style="color: #262626;">该研究开发了一种安全、有效且临床可行的雾化人脐带间充质干细胞外泌体（hUCMSC-EVs）疗法，为肺纤维化提供了一种新型无细胞治疗策略。</span></p> <p><span style="color: #262626;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>外泌体</strong><strong>蛋白组学</strong><strong>检测服务</strong></span><span style="color: #262626;">，揭示了hUCMSC-EVs蛋白富集到很多组织重构的生物学通路中。很多蛋白参与超高分子纤维组成，及细胞骨架组成，这些都与纤维化直接相关，为解释hUCMSC-EVs参与肺组织的纤维化重建提供了分子层面的证据。</span></p> <section><img src="https://img.medsci.cn/c9c2b4de33e5ea1028496e3332d34819e1043d9e9bf5f214a82c10d6e8e139ac.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="3">7</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：华中科技大学同济医学院附属同济医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>J Hepatol (IF: 33)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway</strong></span></p> <p><span style="color: #262626;">该研究发现了核定位的谷氨酰胺转移酶2（TGM2）介导的H3Q5ser 修饰通过MYC 信号通路促进肝细胞癌进展。TGM2可作为HCC的预后生物标志物，靶向其谷氨酰胺转移酶活性可能是抑制HCC进展的有效策略。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>20K人类蛋白组芯片</strong><strong>检测</strong><strong>服务</strong></span><span style="color: #0987e0;">，助力研究团队发现了转录中介因子TRIM28可以直接和TGM2结合。TRIM28可以介导TGM2向MYC募集，促进 H3Q5ser 修饰 MYC 靶基因。</span></p> <section><img src="https://img.medsci.cn/1f2f2a7fecbff14f48e68eb7681b6b744c26d140053635419b5e3866eae8ad5f.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>08</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：南方医科大学珠江医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Gut</strong><strong> (IF:</strong><strong>26.2</strong><strong>)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway</strong></span></p> <p><span style="color: #262626;">该研究揭示了一种特定的肽聚糖片段<span class="">N-乙酰胞壁酸</span>（NAM）通过靶向并阻断AKT1磷酸化的方式调控下游信号通路，发挥治疗结直肠癌的创新机制。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>20K人类蛋白组芯片靶</strong><strong>点筛选</strong><strong>和SPR验证</strong><strong>靶点结合的检测服</strong><strong>务</strong></span><span style="color: #0987e0;">，助力研究团队发现了AKT1是NAM的直接结合靶点蛋白。</span></p> <section><img src="https://img.medsci.cn/2fc19f5da74b002de61efe27ae7635f37e2f425a51600859f1d3a2a3c03ef5a1.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>0</strong><strong title="" data-original-title="" data-num="5">9</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：华中科技大学同济医学院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models</strong></span></p> <p><span style="color: #262626;">这项研究通过高内涵筛选发现了一种低毒性的抗衰老天然产物灵芝酸A，并证实了灵芝酸A能够预防多个物种的衰老，为开发新型抗衰老药物提供了新思路。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>20K人类蛋白组芯片</strong><strong>检测服务</strong></span><span style="color: #0987e0;">，助力研究团队发现了灵芝酸A可以直接与TCOF1结合以维持核糖体稳态，从而减轻多种细胞衰老表型。</span></p> <section><img src="https://img.medsci.cn/2730a9cc80fa9ba363736eeaf174e93a345cc98c428a34d13c68ee3b3a196268.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>10</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：首都儿科研究所</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Parallel comparison of T cell and B cell subpopulations of adenoid hypertrophy and tonsil hypertrophy of children</strong></span></p> <p><span style="color: #262626;">该研究首次在单细胞水平揭示了儿童腺样体肥大与扁桃体肥大的免疫微环境差异，阐明了腺样体以免疫抑制为主导、扁桃体以适应性免疫应答为主的机制。</span></p> <p><span style="color: #0987e0;">华盈生物提供的</span><span style="color: #ff0000;"><strong>Luminex 细胞因子检测服务</strong></span><span style="color: #0987e0;">协助团队对分选的 B 细胞与T 细胞分泌的关键细胞因子进行了深度分析，揭示了腺样体肥大组织具有更强的免疫抑制特性及较弱的免疫反应能力。</span></p> <section><img src="https://img.medsci.cn/80da1cf2f923ed74468c394c12cefce6f8a5f14e47c8369181091e186238f561.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section><strong style="color: #0987e0;">11</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：北京大学肿瘤医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Nat Commun (IF: 15.7)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy</strong></span></p> <p><span style="color: #262626;">该研究系统阐明了FGFR2抑制剂通过NF2-YAP-MST1轴诱导坏死性凋亡的机制，并揭示了IL-8/PD-L1介导的免疫逃逸。联合FGFR2抑制剂与免疫检查点阻断剂的策略为ESCC治疗提供了新方向，具有重要临床转化价值。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>细胞因子检测服务</strong></span><span style="color: #0987e0;">，助力研究团队发现了坏死性凋亡通过IL-8上调PD-L1的表达，介导免疫逃逸。</span></p> <section><img src="https://img.medsci.cn/4a58b4b2e62ccbfdb204a39430a48ae8f41c7875f81dd4c86b4f701d05e1a909.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>12</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：南方医科大学南方医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Cancer Commun (IF: 24.9)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis</strong></span></p> <p><span style="color: #262626;">该项研究发现了肿瘤相关巨噬细胞高表达的SPHK1在结直肠癌肝转移（CRLM）发生和进展中作用机制，并提示联合SPHK1阻断剂和抗PD-1治疗可能成为一种有前途的治疗方案。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>Luminex细胞因子检测服务</strong></span><span style="color: #0987e0;">，助力解析了肿瘤细胞通过分泌趋化因子征募SPHK1+ TAMs，为揭示SPHK1调控肿瘤免疫微环境的机制提供了关键证据。</span></p> <section><img src="https://img.medsci.cn/1adfab29dec6f345ba7d92f6ea722120b7bad1867cd78f1361cbb357b712322b.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>13</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：华中科技大学同济医学院附属协和医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>Sci Bull  (IF: 21.1)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Initial cardioplegic flush with crystalloid cardioplegia improves donor heart preservation and function via NR4A3 upregulation and metabolic reprogramming</strong></span></p> <p><span style="color: #262626;">该项研究提出了一种创新的供体心脏获取和保存方法，使用晶体停搏液（CC）联合威斯康星大学（UW）保存液。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>PEX100信号通路磷酸化抗体芯片检测分析服务</strong></span><span style="color: #0987e0;">，精准解析了CC+UW干预下心肌细胞信号通路的动态变化，揭示了该方法通过抑制NF-κB通路激活，减少炎症反应与能量消耗，提升心脏保存效果。</span></p> <section><img src="https://img.medsci.cn/779e5b4980f645ec7123aa933f79176ee3bfdf639b1db7bc3dcf9799f3f936fa.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section> <section></section> </section> <section> <section style="color: #0987e0;"><strong>14</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：中国人民解放军总医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>J Clin Invest  (IF: 13.6)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling</strong></span></p> <p><span style="color: #262626;">这项研究发现了在膀胱癌中，天然代谢物天冬酰胺可以直接结合RIG-I，促进其降解，从而抑制IFN信号和抗肿瘤免疫。提出了左旋天冬酰胺酶联合抗PD-1治疗的新策略。</span></p> <p><span style="color: #0987e0;">华盈生物提供的</span><span style="color: #ff0000;"><strong> Luminex细胞因子检测服务</strong></span><span style="color: #0987e0;">协助团队解析了肿瘤细胞与免疫微环境的互作机制。通过高通量筛选多种细胞因子与趋化因子，发现了抑制天冬酰胺可促进肿瘤细胞分泌CCL5，从而招募CD8+ T细胞浸润，增强抗肿瘤免疫的分子机制。</span></p> <section><img src="https://img.medsci.cn/dc2139766ca2f6fa042924c5897485525b35c9188b358aceffeb0c218a6e543e.jpg" /></section> </section> </section> </section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>15</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：复旦大学附属中山医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong>J Exp Clin Cancer Res (IF:12.8)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint</strong></span></p> <p><span style="color: #262626;">该研究揭示了DCDC2是肝内胆管癌（ICC）的新型肿瘤相关抗原，其通过稳定ENO1蛋白，一方面促进肿瘤进展，另一方面通过FGL1-LAG3检查点抑制CD8+T细胞功能。靶向该轴为ICC诊断和治疗提供了新策略。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>20K人类蛋白组芯片自身抗体筛选的检测服务</strong></span><span style="color: #0987e0;">，助力研究团队发现了血清中DCDC2自身抗体可作为早期诊断ICC的生物标志物。这为解析DCDC2是一种新型肿瘤相关抗原提供了强有力的证据支持。</span></p> <section><img src="https://img.medsci.cn/7db1b06444854e787cb6411ca60238c1f794e614b1f9408d364fdf1e78082773.jpg" /></section> </section> </section> </section> </section> </section> </section> <section data-tools="135编辑器" data-id="157292"> <section> <section> <section> <section> <section> <section> <section style="color: #0987e0;"><strong>16</strong></section> </section> </section> </section> </section> <section> <section style="color: #333333;" data-autoskip="1"> <p><span style="color: #262626;"><strong>合作单位</strong>：中山大学孙逸仙纪念医院</span></p> <p><span style="color: #262626;"><strong>期刊名称</strong>：</span><span style="color: #ff0000;"><strong><span class="">eBioMedicine</span> (IF: 10.8)</strong></span></p> <p><span style="color: #262626;"><strong>文章标题</strong>：</span><span style="color: #262626;"><strong>TCL1A in naïve B cells as a therapeutic target for type 1 diabetes</strong></span></p> <p><span style="color: #262626;">本研究发现了T1D患者早期B细胞的功能异常，尤其是naïve B细胞比例增加，且其AKT激酶共激活因子TCL1A表达上调。靶向TCL1A能降低naïve B细胞数量，改善葡萄糖耐量。该成果为T1D治疗提供了新的潜在靶点和治疗策略。</span></p> <p><span style="color: #0987e0;">华盈生物为该研究提供了</span><span style="color: #ff0000;"><strong>PEX100信号通路磷酸化抗体芯片检测服务</strong></span><span style="color: #0987e0;">，助力研究团队发现了TCL1A主要调PI3K/AKT途径，揭示了TCL1A可以通过AKT2途径调节B细胞的生存和增殖，促进了T1D中自身反应性B细胞的存活。</span></p> <p><img src="https://img.medsci.cn/8ef86fdfb78281e5795f6d7f0e7282e9ca46308a09120cd5e030c6d8c050ea11.jpg" /></p> </section> </section> </section> </section> </section> <p><span style="color: #262626;">回顾过去一年，我们倍感荣幸能够参与到这场深刻改变生命科学认知边界的进程中。从揭示疾病机制的分子基础，到绘制组织功能的时空图谱，每一项令人瞩目的研究成果背后，都标志着我们对生命复杂性的理解又迈出了坚实的一步。</span></p> <p><span style="color: #262626;">展望未来，生命科学的探索将向着更整合、更动态、更空间精准的方向不断深化。我们将继续以前瞻性的视野，持续迭代与拓展我们的技术平台——无论是蛋白组覆盖的广度和深度、还是空间分辨率与单细胞精度的极限，我们都将不懈追求。我们坚信，蛋白组学，特别是其空间与动态维度，将是解锁下一轮生物学突破的核心钥匙。</span></p> <p><span style="color: #262626;">我们期待，在新的一年里，继续以最坚实的技术平台、最专业的科学支持与最开放的协作精神，与每一位致力于探索未知的科学家并肩前行。让我们携手，共同将更多的科学假设转化为颠覆性的发现，在描绘生命奥秘的宏伟蓝图上，增添更多决定性的笔触。</span></p> <section> <section style="color: #0987e0000;"></section> <p style="color: #595959;"><span style="color: #0987e0;"><strong>业务咨询400-869-2936或17316301592（微信同号）</strong></span></p> <section style="color: #0987e0000;" data-role="title" data-tools="135编辑器" data-id="101167"> <section> <section> <section> <section> <section style="color: #ffffff;" data-brushtype="text"> <p><span style="color: #000000;"><strong>相关文献</strong></span></p> </section> </section> </section> </section> </section> </section> <p><span style="color: #262626;">1.Zhang, Y., et al., Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 2025. 188(24):6754-6773.e29.</span></p> <p><span style="color: #262626;">2.Wang, X., et al., An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell, 2025. 188(16):4225-4238.e12.</span></p> <p><span style="color: #262626;">3.Song, H., et al., Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer Cell, 2025. 43(3):503-518.e10.</span></p> <p><span style="color: #262626;">4.Wang, G.Z., et al., Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers. Signal Transduct Target Ther, 2025. 10(1):290.</span></p> <p><span style="color: #262626;">5.Luo, Z., et al., A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade. Signal Transduct Target Ther, 2025. 10(1):362.</span></p> <p><span style="color: #262626;">6.Li, M., et al., Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduct Target Ther, 2025. 10(1):179.</span></p> <p><span style="color: #262626;">7.Dong, R., et al., TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J Hepatol, 2025. 83(1):105-118.</span></p> <p><span style="color: #262626;">8.Hu, M., et al., Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway. Gut, 2025. 74(8):1230-1245.</span></p> <p><span style="color: #262626;">9.Chen, L., et al., High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models. Nat Commun, 2025. 16(1):2878.</span></p> <p><span style="color: #262626;">10.Yu, Z., et al., Parallel comparison of T cell and B cell subpopulations of adenoid hypertrophy and tonsil hypertrophy of children. Nat Commun, 2025. 16(1):3516.</span></p> <p><span style="color: #262626;">11.Chen, D., et al., Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy. Nat Commun, 2025. 16(1):4128.</span></p> <p><span style="color: #262626;">12.Zhan, Y., et al., Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. Cancer Commun (Lond), 2025. 45(10): 1203-1228.</span></p> <p><span style="color: #262626;">13.Wang, Y., et al., Initial cardioplegic flush with crystalloid cardioplegia improves donor heart preservation and function via NR4A3 upregulation and metabolic reprogramming. Sci Bull (Beijing), 2025. 70(10):1673-1690.</span></p> <p><span style="color: #262626;">14.Wei, W., et al., Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling. J Clin Invest, 2025. 135(8). e186648.</span></p> <p><span style="color: #262626;">15.Wan W et al. The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint. J Exp Clin Cancer Res. 2025;44(1):177.</span></p> <p><span style="color: #262626;">16.Luo S et al. TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. EBioMedicine. 2025;113:105593.</span></p> </section>